Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Interest coverage

Interest coverage at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-19.2×-4.6×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-7.1×-0.8×
PVL
Palvella TherapeuticsPVLA
-174.9×—
Arrowhead Research logo
Arrowhead ResearchARWR
-2.4×+0.9×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-9.3×+1.9×
Precigen logo
PrecigenPGEN
-22,521.4×-22,838×

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

ebit/interest expense=-5.1×

Based on trailing twelve months.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's interest coverage?
BioCryst Pharmaceuticals (BCRX) reported interest coverage of -5.1× in Q1 2026.
How has BioCryst Pharmaceuticals's interest coverage changed year-over-year?
BioCryst Pharmaceuticals's interest coverage decreased by 1593.4% year-over-year, from 0.3× to -5.1×.
What is the long-term trend for BioCryst Pharmaceuticals's interest coverage?
Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's interest coverage has grown at a -18.5% compound annual growth rate (CAGR), from -12.1× to 4.3×.
What does interest coverage mean?
Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.